Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. - Wikidata - awgldk - TriplyDB

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

http://www.wikidata.org/entity/Q33346935

about

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours Neuroendocrine tumors of the gastro-entero-pancreatic system Rare cystic liver lesions: a diagnostic and managing challenge.A new TAG-72 cancer marker peptide identified by phage display.Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression.Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT.Binding of TS1, an anti-keratin 8 antibody, in small-cell lung cancer after 177Lu-DOTA-Tyr3-octreotate treatment: a histological study in xenografted mice.A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides.A new era for the systemic therapy of neuroendocrine tumors.Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome.Stroma targeting nuclear imaging and radiopharmaceuticals.Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study Treatment of endocrine pancreatic tumors.A review of the use of somatostatin analogs in oncology Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.Peptide receptor expression in GEP-NET.Diagnosis of Men-I Syndrome on (68)Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE.Diagnosis and Treatment of Gastrinomas in Multiple Endocrine Neoplasia Type 1 (MEN-1).Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuro endocrine tumours.Primary carcinoid tumour of the kidney: a review of the literature.Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.Biomarkers in abdominal imaging.Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocr Peptide-receptor radionuclide therapy for endocrine tumors.Genomic biomarkers for molecular imaging: predicting the future Peptide receptor therapies in neuroendocrine tumors.Zebularine significantly sensitises MEC1 cells to external irradiation and radiopharmaceutical therapy when administered sequentially in vitro.Non-functioning pancreatic neuroendocrine tumors--a case report and review of literature.Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review.Lutetium-labelled peptides for therapy of neuroendocrine tumours.Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.Radionuclide Therapy for Neuroendocrine Tumors.

P2860

Q24685837-831426C0-38E1-4B42-971C-1A8C1352F74E Q28071978-9B029B42-E3DB-4100-BFDE-B3027AB40753 Q28294432-DC6B661E-CCC8-41BB-8712-C85891C6B5FD Q30446819-6276F776-EAE0-453A-9045-A161D90C2996 Q33362816-C397481C-AD81-4799-92D6-0E99F5A9C1A7 Q33979298-F68FA399-84F1-42A1-958E-5E1536611C55 Q34083332-DBB29C96-EFF2-48FD-99AF-5D94BA745DEA Q34203773-7F46812E-F281-43D6-AB54-3744A973E8A7 Q35148094-56841865-C74A-45FF-BFB2-9D96E6E12773 Q35201583-0627BFA2-E41A-478E-97C6-587FEDAFA8E3 Q35550939-09164DB2-0929-40AC-8F47-860369BC677A Q35731542-C06892F6-E0A1-460D-BE0F-54077FB9B2C0 Q35831439-985AABA6-86AB-499F-834B-D03C445333A4 Q35863865-CEBDCD2C-16E6-4C68-8338-75BFF25020EE Q35922060-2CB16337-EE77-4E1D-8B0A-ABD4A07A8195 Q35999606-7BCC298F-0A63-4A76-A258-E44A51A75C1B Q36008285-C5B5248A-73A5-4FF7-BC5F-8AC07521869B Q36125639-F9FB713E-FE44-44F8-90BD-0D4AD68EF43E Q36239955-B22CC4E9-A650-48BA-9C12-E96B83822A8E Q36833161-293892F7-3DE8-47EE-900D-B22C8BDB5BA0 Q36892294-7AAADB1B-8875-4F4B-B4B6-050B0B23775E Q36904576-DC191A67-C9EA-47BD-816E-12C68DCDA430 Q36957431-274B9B4B-A4BC-4840-B18F-B50349CB6FC1 Q37016985-9B027F66-94A2-436B-A20D-BE37FC824947 Q37077358-A3400FA7-4FAA-42EC-8B35-7B21502171C3 Q37127276-24666E38-8B36-4729-96F4-495D80902B1F Q37214696-6D8146B0-8FC0-4FEF-8CC9-E747EED968FC Q37339032-E1293AFD-87DC-4AA9-9F85-6F52A3CF4A83 Q37425156-F5826B9D-DEA9-49CE-9394-BAA80570C4B6 Q37504690-DE32191F-597A-4EF2-A07E-82A71FF5FFBD Q37508283-B6A6840E-C62F-4218-8D7E-90E15620CCED Q37563878-82D1D0B7-8E33-4443-B89D-A36CC72FF5DA Q37625716-DE6994B0-D1E3-487F-A2FB-F08F63570F9C Q37802274-2F73E470-50D8-4AD7-AAC2-9260ABD321A6 Q37812297-EBC12111-A28C-43F0-B060-F2D1DBD91E57 Q37990411-AE847679-C333-4F4A-9D06-93DFC6198711 Q38271733-2822B631-7374-47F0-87FC-DD1A1680A052 Q38694105-EC19EEBF-4AE2-479F-82C4-6AC14E1E2014 Q38813559-B681C971-1C07-4941-9135-BCA7A13D4DDD Q39144880-9ABFA58A-5681-4651-902C-84A46E09EC07

P2860

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.

http://www.wikidata.org/entity/Q33346935

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Treatment of patients with gas ...... 177Lu-DOTA(0),Tyr3]octreotate.

@ast

Treatment of patients with gas ...... 177Lu-DOTA(0),Tyr3]octreotate.

@en

type

label

Treatment of patients with gas ...... 177Lu-DOTA(0),Tyr3]octreotate.

@ast

Treatment of patients with gas ...... 177Lu-DOTA(0),Tyr3]octreotate.

@en

prefLabel

Treatment of patients with gas ...... 177Lu-DOTA(0),Tyr3]octreotate.

@ast

Treatment of patients with gas ...... 177Lu-DOTA(0),Tyr3]octreotate.

@en

P1433

Q33346935-66B095A4-D49E-4499-ABC2-4EB90819B88E

P1476

Q33346935-DEDEB93F-88EE-4BFE-B29A-B6ED04094E71

P2093

Q33346935-227B348E-1D84-4410-BADA-9F0A80DD3A61

Q33346935-31214A66-71FC-42FB-9A00-4B72820B5D89

Q33346935-3D188088-4CAC-42FD-A7AC-3ECD1432F35E

Q33346935-4132B241-4DD6-4DE1-8EBA-5E5EC6CA54CF

Q33346935-4608086E-4CC1-4050-95F4-5998D8A95637

Q33346935-5B6483C2-1914-41A7-B143-C79D62A87F8E

Q33346935-66C3B640-A42C-48CB-89EF-90FE39E2255C

Q33346935-743D6891-C7D1-4F7D-AFD9-94881ADF1644

Q33346935-83815460-658A-4F2F-9784-CC03F4A4FDCA

Q33346935-84CA1547-3ABB-4BAE-8353-19F01E33DC4F

P2860

Q33346935-349EB8A4-F08F-4E19-B11B-5B76A98FE6D8

Q33346935-3AD50B68-9E40-4FAD-A9B2-C855648980FB

Q33346935-756C6993-3318-4959-9501-36B5F3522AC7

Q33346935-8000547A-2EB5-458A-89D5-3FAF15962A4B

Q33346935-93D8A044-E9D6-4348-9815-11696BA47FDE

Q33346935-A501FB28-6EEA-449E-9C62-640E920D1C37

Q33346935-B1FCFAAD-088D-4A48-8E88-1E1C78A20AF7

Q33346935-CE64B304-35F2-4C3B-AC19-BD68B0B2024E

Q33346935-D5A7860D-DB79-489D-A59B-9C72C6B94B94

P2888

Q33346935-FCE03F9E-7326-4F8D-96D7-F9F2F1CAF480

P304

Q33346935-45D55620-19F6-4AAC-A3D8-180729B964E0

P31

Q33346935-F4CD1CFD-1517-4DB8-8631-B1DE80052625

P356

Q33346935-62FD513F-5DCE-4478-9BA8-5BF7D779A828

P433

Q33346935-EF60FB68-ACA9-4604-9B44-D9CAB16B4E14

P478

Q33346935-423A5F16-E1CB-46EB-B31F-DAE5D30DC750

P577

Q33346935-851166C0-F4ED-4422-B712-BC848C95BEEF

P5875

Q33346935-5A5712E3-9FD2-4E6D-9606-81277F9108F6

P698

Q33346935-3E5BEA30-8C32-4523-9A81-439440ABED60

P921

Q33346935-F462C2B2-C34C-43E3-AB8A-7521A54014D0

P932

Q33346935-E35AD870-ACAA-45D9-B709-BF059F56C8CE

P356

S00259-002-1050-8

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Treatment of patients with gas ...... 177Lu-DOTA(0),Tyr3]octreotate.

@en

P2093

A Srinivasan

http://www.w3.org/2001/XMLSchema#string

B L Kam

http://www.w3.org/2001/XMLSchema#string

C H J van Eijck

http://www.w3.org/2001/XMLSchema#string

D J Kwekkeboom

http://www.w3.org/2001/XMLSchema#string

E P Krenning

http://www.w3.org/2001/XMLSchema#string

J J M Teunissen

http://www.w3.org/2001/XMLSchema#string

J L Erion

http://www.w3.org/2001/XMLSchema#string

M de Jong

http://www.w3.org/2001/XMLSchema#string

P P M Kooij

http://www.w3.org/2001/XMLSchema#string

R A Feelders

http://www.w3.org/2001/XMLSchema#string

P2860

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.

P2888

s00259-002-1050-8

P304

417-422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-002-1050-8

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7986644

http://www.w3.org/2001/XMLSchema#string

P698

12634971

http://www.w3.org/2001/XMLSchema#string

P921

P932

1998890

http://www.w3.org/2001/XMLSchema#string